Literature DB >> 18996835

Does FGF23 toxicity influence the outcome of chronic kidney disease?

Mohammed Shawkat Razzaque.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18996835      PMCID： PMC2721424          DOI： 10.1093/ndt/gfn620

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  44 in total

Review 1.  Fibroblast growth factor 23: roles in health and disease.

Authors:  Erik A Imel; Michael J Econs
Journal:  J Am Soc Nephrol       Date:  2005-07-20       Impact factor: 10.121

Review 2.  FGF-23, vitamin D and calcification: the unholy triad.

Authors:  Mohammed S Razzaque; Rene St-Arnaud; Takashi Taguchi; Beate Lanske
Journal:  Nephrol Dial Transplant       Date:  2005-07-19       Impact factor: 5.992

3.  Association of disorders in mineral metabolism with progression of chronic kidney disease.

Authors:  Stephan Schwarz; Bhairvi K Trivedi; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  Clin J Am Soc Nephrol       Date:  2006-05-17       Impact factor: 8.237

4.  Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism.

Authors:  Hiroshi Nishi; Tomoko Nii-Kono; Shohei Nakanishi; Yuji Yamazaki; Takeyoshi Yamashita; Seiji Fukumoto; Kazuto Ikeda; Akira Fujimori; Masafumi Fukagawa
Journal:  Nephron Clin Pract       Date:  2005-06-14

Review 5.  FGF23 and disorders of phosphate homeostasis.

Authors:  Xijie Yu; Kenneth E White
Journal:  Cytokine Growth Factor Rev       Date:  2005-02-05       Impact factor: 7.638

Review 6.  Role of fibroblast growth factor 23 in health and in chronic kidney disease.

Authors:  Masafumi Fukagawa; Tomoko Nii-Kono; Junichiro J Kazama
Journal:  Curr Opin Nephrol Hypertens       Date:  2005-07       Impact factor: 2.894

Review 7.  Hypophosphatemia: an update on its etiology and treatment.

Authors:  André Gaasbeek; A Edo Meinders
Journal:  Am J Med       Date:  2005-10       Impact factor: 4.965

8.  Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease.

Authors:  Orlando Gutierrez; Tamara Isakova; Eugene Rhee; Anand Shah; Julie Holmes; Gina Collerone; Harald Jüppner; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2005-05-25       Impact factor: 10.121

9.  Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

Authors:  Shohei Nakanishi; Junichiro James Kazama; Tomoko Nii-Kono; Kentaro Omori; Takeyoshi Yamashita; Seiji Fukumoto; Fumitake Gejyo; Takashi Shigematsu; Masafumi Fukagawa
Journal:  Kidney Int       Date:  2005-03       Impact factor: 10.612

Review 10.  Structural and biochemical properties of fibroblast growth factor 23.

Authors:  Takeyoshi Yamashita
Journal:  Ther Apher Dial       Date:  2005-08       Impact factor: 1.762
View more
  32 in total

1.  Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372.

Authors:  Mohammed S Razzaque
Journal:  Expert Opin Ther Pat       Date:  2010-07       Impact factor: 6.674

2.  Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function.

Authors:  Justine Bacchetta; Pierre Cochat; Isidro B Salusky; Katherine Wesseling-Perry
Journal:  Pediatr Nephrol       Date:  2012-02-05       Impact factor: 3.714

Review 3.  The role of Klotho in energy metabolism.

Authors:  M Shawkat Razzaque
Journal:  Nat Rev Endocrinol       Date:  2012-05-29       Impact factor: 43.330

Review 4.  [FGF23 and Klotho: the new cornerstones of phosphate/calcium metabolism].

Authors:  J Bacchetta; P Cochat; I B Salusky
Journal:  Arch Pediatr       Date:  2011-04-16       Impact factor: 1.180

5.  FGF23-induced hypophosphatemia persists in Hyp mice deficient in the WNT coreceptor Lrp6.

Authors:  Kazuyoshi Uchihashi; Teruyo Nakatani; Regina Goetz; Moosa Mohammadi; Xi He; Mohammed S Razzaque
Journal:  Contrib Nephrol       Date:  2013-05-03       Impact factor: 1.580

Review 6.  Phosphate sensing.

Authors:  Clemens Bergwitz; Harald Jüppner
Journal:  Adv Chronic Kidney Dis       Date:  2011-03       Impact factor: 3.620

7.  Important abnormalities of bone mineral metabolism are present in patients with coronary artery disease with a mild decrease of the estimated glomerular filtration rate.

Authors:  Emilio González-Parra; Álvaro Aceña; Óscar Lorenzo; Nieves Tarín; María Luisa González-Casaus; Carmen Cristóbal; Ana Huelmos; Ignacio Mahíllo-Fernández; Ana María Pello; Rocío Carda; Ignacio Hernández-González; Joaquín Alonso; Fernando Rodríguez-Artalejo; Lorenzo López-Bescós; Alberto Ortiz; Jesús Egido; José Tuñón
Journal:  J Bone Miner Metab       Date:  2015-08-23       Impact factor: 2.626

Review 8.  Can features of phosphate toxicity appear in normophosphatemia?

Authors:  Satoko Osuka; Mohammed S Razzaque
Journal:  J Bone Miner Metab       Date:  2012-01-05       Impact factor: 2.626

Review 9.  From bone abnormalities to mineral metabolism dysregulation in autosomal dominant polycystic kidney disease.

Authors:  Djalila Mekahli; Justine Bacchetta
Journal:  Pediatr Nephrol       Date:  2013-01-24       Impact factor: 3.714

Review 10.  αKlotho and Chronic Kidney Disease.

Authors:  J A Neyra; M C Hu
Journal:  Vitam Horm       Date:  2016-03-24       Impact factor: 3.421
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.